Astellas Pharma and Pfizer have announced unprecedented results from the pivotal Phase 3 EV-303 clinical trial (KEYNOTE-905), with the combination of PADCEV (enfortumab vedotin) and MSD's KEYTRUDA (pembrolizumab) delivering significant survival benefits for cisplatin-ineligible patients with muscle-invasive bladder cancer. …
New combination therapy sets landmark survival benchmark in bladder cancer treatment
October 19, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
US childhood vaccine move away from combinations contrasts with Australia’s national schedule
August 12, 2026 - - Latest News -
A sage appointment that puts DBG Health another step closer to a serious understanding of decision-making
August 12, 2026 - - Latest News -
Former minister joins DBG Health board as company broadens healthcare ambition
August 12, 2026 - - Latest News -
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News -
Percheron turns to former Arovella chief Michael Baker for next phase of HMBD 002 development
August 10, 2026 - - Latest News -
Australian company points to encouraging survival signal in mesothelioma CAR-T study
August 10, 2026 - - Australian Biotech -
GBMA White Paper calls for reforms to strengthen supply chain resilience
August 10, 2026 - - Latest News